Skip to main content

Table 5 Enrollment and outcomes in studies using Pritchard or Zuspan, or any Dhaka regimen

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

  Enrollment N Outcomes N (%)
Study Subjects Pre-eclampsia Eclampsia Affected patella reflex Respiratory depression Oliguria Skipped dose Calcium gluconate Maternal death
All Due to MgSO4
PRITCHARD OR ZUSPAN
Altman 1 5055 5055 0 59 4 514 114 1875 14 11 0
Eclampsia Collab. Trial A 2 453 0 453   35     17  
Eclampsia Collab. Trial B 3 388 0 388   32     10  
TOTAL 5896 5055 841 59 (1.0) 118 (2.0) 114 (1.9) 187 (3.2) 14 (0.2) 38 (0.6) 0 (0)
DHAKA (ALL)
Begum 65 0 65 5 0 0    0 0
Shilva 25 0 25 8   5 137   0 0
Shilva 6 25 0 25 2   1 38   0 0
TOTAL 115 0 115 15 (13) 0 (0) 6 (5.2) 16 (13.9) 0 (0) 0 (0) 0 (0)
  1. 1 Subjects received either Pritchard or Zuspan regimen; 2 Study of Pritchard or Zuspan regimen vs diazepam; 3 Study of Pritchard or Zuspan regimen vs phenytoin; 4 4 Women had respiratory depression and absent tendon reflex; 5 Includes 114 women who stopped treatment because of oliguria or renal failure, 26 women who stopped treatment because of respiratory depression or arrest, and 47 women who stopped treatment because of absent tendon reflex; 6 Received Dhaka modified regimen; 7 8 Skipped because loss of knee-jerk and 5 because of oliguria; 8 2 Skipped because loss of knee-jerk and 1 because of oliguria.